Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine M Lovly

Showing results (1-10 of 123) with videos related to

Pageof 13
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Combating acquired resistance to tyrosine kinase inhibitors in lung cancerChristine M Lovly
Molecular Cancer|February 20, 2018
Mechanisms of receptor tyrosine kinase activation in cancerZhenfang Du, Christine M Lovly
Cancer Discovery|October 5, 2016
Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therapy in Lung CancerHuan Qiao, Christine M Lovly
Cancer Discovery|July 9, 2015
Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung CancerEiki Ichihara, Christine M Lovly
Science Translational Medicine|February 11, 2012
Escaping ALK inhibition: mechanisms of and strategies to overcome resistanceChristine M Lovly, William Pao
Translational Lung Cancer Research|April 14, 2023
Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative reviewAakash Desai, Christine M Lovly
Current Treatment Options in Oncology|July 27, 2012
Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLCChristine M Lovly, Leora Horn
Nature Reviews. Clinical Oncology|February 1, 2011
Lung cancer in 2010: One size does not fit allChristine M Lovly, David P Carbone
The Journal of Pathology|January 19, 2018
Established, emerging and elusive molecular targets in the treatment of lung cancerJean-Nicolas Gallant, Christine M Lovly
Cancer Discovery|July 4, 2018
Stop fRETting the Target: Next-Generation RET Inhibitors Have ArrivedWade T Iams, Christine M Lovly
Pageof 13

Showing results (1-10 of 123) with videos related to

Sort By:
Pageof 13
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Combating acquired resistance to tyrosine kinase inhibitors in lung cancerChristine M Lovly
Molecular Cancer|February 20, 2018
Mechanisms of receptor tyrosine kinase activation in cancerZhenfang Du, Christine M Lovly
Cancer Discovery|October 5, 2016
Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therapy in Lung CancerHuan Qiao, Christine M Lovly
Cancer Discovery|July 9, 2015
Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung CancerEiki Ichihara, Christine M Lovly
Science Translational Medicine|February 11, 2012
Escaping ALK inhibition: mechanisms of and strategies to overcome resistanceChristine M Lovly, William Pao
Translational Lung Cancer Research|April 14, 2023
Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative reviewAakash Desai, Christine M Lovly
Current Treatment Options in Oncology|July 27, 2012
Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLCChristine M Lovly, Leora Horn
Nature Reviews. Clinical Oncology|February 1, 2011
Lung cancer in 2010: One size does not fit allChristine M Lovly, David P Carbone
The Journal of Pathology|January 19, 2018
Established, emerging and elusive molecular targets in the treatment of lung cancerJean-Nicolas Gallant, Christine M Lovly
Cancer Discovery|July 4, 2018
Stop fRETting the Target: Next-Generation RET Inhibitors Have ArrivedWade T Iams, Christine M Lovly
Pageof 13